Scarica l'app Stockscreener
46.81
1.41%
0.65
Dopo l'orario di chiusura:
46.55
-0.26
-0.56%
Precedente Chiudi:
$46.16
Aprire:
$46.74
Volume 24 ore:
1.25M
Relative Volume:
0.88
Capitalizzazione di mercato:
$5.70B
Reddito:
$47.30M
Utile/perdita netta:
$-408.73M
Rapporto P/E:
-13.05
EPS:
-3.5865
Flusso di cassa netto:
$-303.86M
1 W Prestazione:
-3.74%
1M Prestazione:
-16.56%
6M Prestazione:
-6.40%
1 anno Prestazione:
+33.02%
Intervallo 1D:
$46.08
$47.80
Intervallo di 1 settimana:
$46.07
$49.98
Portata 52W:
$27.07
$61.76
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Nome
Scholar Rock Holding Corp
Settore
Industria
Telefono
857-259-3860
Indirizzo
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
46.81 | 5.92B | 47.30M | -408.73M | -303.86M | -3.5865 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-01-09 | Iniziato | Citigroup | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-10-09 | Iniziato | BofA Securities | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-15 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Ripresa | Jefferies | Buy |
| 2025-07-30 | Ripresa | Raymond James | Strong Buy |
| 2025-07-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-26 | Reiterato | H.C. Wainwright | Buy |
| 2024-10-07 | Reiterato | H.C. Wainwright | Buy |
| 2024-03-28 | Iniziato | Raymond James | Strong Buy |
| 2023-10-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-04-03 | Ripresa | Piper Sandler | Overweight |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-07-12 | Iniziato | Truist | Buy |
| 2022-03-23 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-03-12 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Scholar Rock Holding Corp Borsa (SRRK) Ultime notizie
Investigation launched into Scholar Rock's offi... - Pluang
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm - TradingView
Scholar Rock Holding Corp. Cash Flow – HAN:2QK - TradingView
Net income of Scholar Rock Holding Corp. – HAN:2QK - TradingView
EBIT of Scholar Rock Holding Corp. – HAN:2QK - TradingView
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Form 4 Scholar Rock Holding Corp For: 26 September By Investing.com - Investing.com Canada
No common shares appear in Scholar Rock (SRRK) COO Keith Woods’s reported position after a gift to a trust. - Stock Titan
Scholar Rock Holding Corp (SRRK) Gains Wedbush Spotlight Amid Valuation and Insider Activity Insights - GuruFocus
Scholar Rock added to Wedbush's Best Ideas List - Seeking Alpha
Piper Sandler reiterates Scholar Rock stock rating on uptake view By Investing.com - Investing.com Australia
Wedbush Rates Scholar Rock (SRRK) Outperform Amid Attractive Pri - GuruFocus
Piper Sandler reiterates Scholar Rock stock rating on uptake view - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SRRK Maintains Buy Rating by Truist Securities -- Price Target R - GuruFocus
Truist raises Scholar Rock stock price target on drug pricing update By Investing.com - Investing.com Australia
Truist raises Scholar Rock stock price target on drug pricing update - Investing.com
Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating - Yahoo Finance
Scholar Rock (SRRK) Short Interest & Short Float | Updated Sep 2026 $SRRK - MarketBeat
No payment changed hands when Scholar Rock (SRRK) CEO David Hallal transferred 36,652 shares to a family trust. - Stock Titan
Scholar Rock’s Isembyld approval sets up rapid sales ramp - S&P Global
Scholar Rock Holding Corporation (SRRK) stock price, news, quote and history - Yahoo Finance UK
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade - MarketBeat
Weight-loss drug developers line up to tap lucrative market as competition heats up - reuters.com
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
SRRK Maintains Overweight Rating by JP Morgan -- Price Target Ra - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
JPMorgan raises Scholar Rock stock price target to $70 on launch outlook - Investing.com Nigeria
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding (SRRK) Won FDA Approval, Is The Stock Still Trading At A Discount? - Simply Wall Street
Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group - MarketBeat
HC Wainwright Lowers Earnings Estimates for Scholar Rock - MarketBeat
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale? - Insider Monkey
Scholar Rock (NASDAQ: SRRK) Updates FDA Safety Requirements for ISEMBYLD Post-Approval - Kalkine Media
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions - Yahoo Finance
Piper Sandler raises Scholar Rock stock price target on pricing By Investing.com - Investing.com South Africa
Scholar Rock (SRRK) Gains FDA Approval for Isembyld Amid Post-Ma - GuruFocus
Scholar Rock Shares Fall After Barclays Downgrade - marketscreener.com
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says - marketscreener.com
Scholar Rock (SRRK) Shares Drop Amid Barclays Downgrade Despite FDA Approval - GuruFocus
Scholar Rock clarifies post-marketing requirements for ISEMBYLD after FDA approval - Investing.com
Scholar Rock (NASDAQ:SRRK) Shares Down 7.1%Here's What Happened - MarketBeat
Form 8K Scholar Rock Holding Corp For: 15 September By Investing.com - Investing.com Australia
SRRK Maintained by Wedbush -- Price Target Raised to $70 - GuruFocus
UBS reiterates Buy on Scholar Rock stock, keeps $60 price target - Investing.com
Scholar Rock Updates FDA Post-Marketing Safety Requirements for ISEMBYLD Following Investor Call Correction - kalkinemedia.com
H.C. Wainwright raises Scholar Rock stock price target on FDA approval - Investing.com UK
SRRK Maintained by HC Wainwright & Co. -- Price Target Raised to $70 - GuruFocus
Barclays downgrades Scholar Rock stock rating on valuation By Investing.com - Investing.com Australia
Scholar Rock Holding Corp Azioni (SRRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Scholar Rock Holding Corp Azioni (SRRK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gilman Michael | Director |
Jul 01 '26 |
Sale |
53.87 |
2,544 |
137,058 |
59,511 |
| Burow Kristina | Director |
Jul 01 '26 |
Sale |
53.74 |
3,053 |
164,064 |
114,657 |
| Reed Joshua | Director |
Jul 01 '26 |
Sale |
53.74 |
3,053 |
164,067 |
19,518 |
| Peng Katie | Director |
Jul 01 '26 |
Sale |
53.88 |
5,446 |
293,405 |
34,301 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):